Bullous pemphigoid is an autoimmune disease of the skin characterized by large, tense bullae resulting in significant morbidity in affected individuals. The diagnosis of bullous pemphigoid may present challenges due to clinical similarities with various other bullous eruptions. Frequently, epidemiological features can provide clues to the diagnosis of bullous pemphigoid, with histologic analysis commonly required for definitive diagnosis. This case study illustrates the typical clinical and histologic findings seen in bullous pemphigoid patients and briefly discusses the differential diagnosis. An in-depth understanding of the intricate pathophysiology is essential in order to educate patients. After diagnosis and appropriate workup, an array of treatment approaches, including topical and systemic corticosteroids, immunosuppressive agents, antibiotics, chemotherapeutic agents, and even monoclonal antibodies, may be utilized individually or in combination to achieve an optimal therapeutic response.
B
ullous diseases are a group of dermatological conditions characterized clinically by fl uid-fi lled blisters of varying sizes and histological depths within the epidermis and dermis. Many of these eruptions have similar presentations and overlapping characteristics. However, key clinical and histopathological diff erences allow for distinction between these bullous disease subtypes. Here, we discuss a patient who presented to our outpatient clinic with widespread bullae and was subsequently diagnosed with bullous pemphigoid.
CASE PRESENTATION
A 59-year-old Hispanic man presented to us with a 1-year history of a diff use, pruritic rash distributed over the entire body, including the buttocks and groin. At the time of presentation, he was not receiving any form of topical or systemic therapy. Past treatments included oral penicillin and corticosteroid injections, with minimal to no relief. Th e patient reported prior oral lesions but denied any current mucosal or joint involvement. Th e patient reported no signifi cant past medical history, surgical history, allergies to medications, or a family history of skin disease.
Upon physical examination, the patient exhibited multiple superfi cial ulcerations with purulence and crusting involving the scalp (Figure 1) extremities, and bilateral lower extremities. Of note, the left neckline showed a 4 cm × 2 cm erythematous, superfi cial area of ulceration with associated crusting and several 1 cm pustules extending onto the left upper chest (Figure 2) . In addition, erythema and diff use hyperpigmentation were noted in a photo-distributed area around the neck and over the upper back. Large, fl accid bullae were observed over the bilateral lower extremities and the inner thighs (Figure 3 ). Gentle pressure applied to the edge of a bulla failed to elicit enlargement of the blister or separation of the superfi cial layers of the skin (negative Nikolsky's sign).
A skin biopsy was taken from the upper back for hematoxylin and eosin (H&E) staining. A second biopsy from an individual bulla on the knee was also obtained for immunofl uorescence staining. A provisional diagnosis of bullous pemphigoid was made based on clinical fi ndings, and the patient was prescribed 40 mg prednisone twice a day for 1 month, as well as 500 mg cephalexin three times daily for 10 days. the patient was prescribed halobetasol propionate 0.05% ointment for topical application to aff ected areas.
Histologically, the H&E stain showed the presence of subepidermal blister formation with reepithelialization at the base ( Figure 4) . Th e blister was fi lled with serous exudate and red blood cells. In the dermis, collections of perivascular lymphocytes with scattered neutrophils and eosinophils were observed. Th e immunofl uorescence biopsy showed linear deposits of immunoglobulin (Ig) G and C3 along the basement membrane zone ( Figure 5 ). Immunofl uorescence was negative for IgA and IgM. Both biopsy specimens confi rmed a diagnosis of bullous pemphigoid.
DISCUSSION
Bullous pemphigoid is an autoimmune blistering skin disease characterized clinically by the presence of large, tense blisters occurring anywhere on the body, but typically seen in preferred locations, including the trunk and fl exural regions of the limbs, groin, and lower abdomen. Th ese lesions often ulcerate, become pustular, or rupture with resultant crusting (1) . Bullous pemphigoid usually occurs in older patients in the sixth to eighth decades of life, with a predilection for males (2) . According to population-based cohort studies in the United Kingdom, the incidence of bullous pemphigoid is 4.3 cases per 100,000 person-years (3) . Approximately 10% to 30% of patients with bullous pemphigoid have involvement of the mucous membranes, which is usually transient (4) . Bullous pemphigoid, although associated with a relatively low mortality, may cause high morbidity in a percentage of aff ected individuals (5) .
Clinically, the cutaneous fi ndings in bullous pemphigoid can be highly variable. In the initial phase of the disease, nonspecifi c symptoms such as generalized pruritus with or without associated eczematous, excoriated, papular, and/or urticarial lesions may predominate. Th e bullous phase of the disease follows, being characterized by tense vesicles or bullae containing serous or blood-tinged fl uid (4). Th ese blisters can be present on an erythematous base or normal skin, often with associated excoriated papules and/or plaques. Th e blisters of bullous pemphigoid usually range from 0.5 to 4 cm in diameter, may persist for several days, and frequently rupture, leaving erosions, ulcerations, or crusted lesions (1) . Blisters in bullous pemphigoid are often symmetrically distributed over the body surface and favor fl exural areas, including the groin, axillae, and lower abdomen (4) . Th e bullae of bullous pemphigoid do not extend laterally, thus exhibiting a negative Nikolsky's sign, and usually heal without scarring. Upon resolution of infl ammatory lesions, hyperpigmented or hypopigmented areas of postinfl ammatory change may be seen (2) . Mucous membrane involvement, while uncommon, may aff ect the oral cavity, eyes, nose, pharynx, esophagus, or anogenital regions and is associated with higher morbidity and mortality (5) .
Histologically, subepidermal bullae are the characteristic pathological fi nding. Th ese bullae, as in our case, are caused by linear deposition of circulating IgG antibodies and C3 along the basement membrane zone of the dermal-epidermal junction (1, 4) . Th ese IgG antibodies are specifi cally directed against hemidesmosome-associated proteins located in the basement membrane, known as antigens BP230 and BP180 (6, 7) . Once deposited, these IgG antibodies attract complement C3, which, upon deposition, elicits an infl ammatory response. An infl ammatory cascade results with the additional attraction of neutrophils, lymphocytes, and eosinophils, which deposit in the dermis or within the blister cavity (6, 7) . Th e release of protease enzymes from accumulated neutrophils damages the junctional adhesion complexes responsible for dermal and epidermal cohesion. Th e end result of this infl ammation is the separation of the epidermis from the dermis, resulting in blister formation (8) .
Th e early, nonbullous phase of bullous pemphigoid is often clinically nonspecifi c. Th us, the diff erential diagnosis of early bullous pemphigoid is broad and includes conditions such as prurigo, urticaria, allergic contact dermatitis, arthropod reactions, pemphigus foliaceus, scabies, and vasculitis. Many of these conditions can be distinguished from bullous pemphigoid based on clinical history. When history and physical examination fail to narrow the diagnosis, biopsy with immunofl uorescence analysis will invariably distinguish early bullous pemphigoid from these other conditions (4). In the bullous stage of bullous pemphigoid, multiple disorders need to be diff erentiated (Table) . While the clinical context, especially the nature of the blister, may provide clues to the diagnosis, immunofl uorescence analysis is often required for defi nitive diagnosis, as in our case (1-4) .
In addition, there is a somewhat controversial association between bullous pemphigoid and underlying internal malignancy. In multiple publications, bullous pemphigoid has been reported to develop with increased frequency in patients with malignant neoplasms of various internal organ systems, including the digestive tract, lung, and urinary bladder (9, 10 ). An increased risk of lymphoproliferative malignancies has also been suggested (10) . However, other studies have shown that patients with bullous pemphigoid do not have an increased incidence of internal malignancy when compared to the general population matched for age and sex (9) . Numerous case-control studies indicate that an increased risk of malignancy in bullous pemphigoid patients appears to be marginal and is probably related to the older age of patients with bullous pemphigoid rather than the disease process itself (4, 10). Currently, extensive studies for underlying internal malignancy should not be the standard of care in patients with bullous pemphigoid, unless history and physical exam indicate otherwise (9) . Nevertheless, this blistering disease does appear to develop concomitantly with an underlying neoplasm in rare instances. Th erefore, bullous pemphigoid patients with other systemic symptoms or atypical presentations, such as younger age, may require investigative cancer screening (4) .
Patients with bullous pemphigoid usually carry a favorable prognosis, with spontaneous resolution noted in a small percentage of patients within months to years of initial presentation. However, bullous pemphigoid is frequently a chronic disease with exacerbations and remissions. Due to the healing capability of blisters in bullous pemphigoid, mortality is low. More widespread involvement with multiple bullae and ulcerations increases the mortality risk, necessitating immediate intervention (1). Topical and systemic corticosteroids along with other immunosuppressive medications make up the primary treatment regimen for most patients with bullous pemphigoid. In limited or localized cutaneous disease, high-potency topical corticosteroids and/or topical immunomodulators, such as tacrolimus, may be suffi cient. However, for more widespread disease, the use of systemic corticosteroids frequently halts further blister formation within days of treatment initiation. Prednisone, dosed at 0.5 to 1.0 mg per kg of body weight daily, is generally considered to be the fi rst-line treatment modality for controlling bullous pemphigoid. In milder cases of bullous pemphigoid, other antiinfl ammatory medications such as dapsone and tetracyclines have proven eff ective. Dapsone has been shown to produce a favorable response in treating the mucosal lesions of bullous pemphigoid. In patients with chronic bullous pemphigoid, systemic corticosteroids are commonly used initially to rapidly control the disease, with eventual tapering and introduction of maintenance immunosuppressive medications. In this commonly used regimen, oral prednisone is initiated at a dose of 0.5 to 1.0 mg per kg of body weight per day, leading to no new blister formation within 1 to 2 weeks. Th ereafter, the corticosteroid dose is gradually tapered and an immunosuppressive drug such as azathioprine, methotrexate, or mycophenolate mofetil is added for maintenance Widespread dermal ulcerations and bullaetherapy (1, 4) . A period of medication overlap exists until systemic corticosteroids are eventually discontinued (4, 11) . Th e selection of an immunosuppressive drug for maintenance therapy is often made based on side eff ect profi le, cost, and practicality. For elderly patients, who make up the majority of bullous pemphigoid cases, methotrexate may be the most cost-eff ective and tolerable option (11) . Finally, in clinically severe disease, more aggressive treatment with plasmapheresis or cyclophosphamide may be required for therapeutic success, with intravenous immunoglobulin and rituximab treatment used in highly treatment-resistant cases (1, 4) .
